377 related articles for article (PubMed ID: 34047271)
1. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021.
Martínez-Baz I; Miqueleiz A; Casado I; Navascués A; Trobajo-Sanmartín C; Burgui C; Guevara M; Ezpeleta C; Castilla J;
Euro Surveill; 2021 May; 26(21):. PubMed ID: 34047271
[TBL] [Abstract][Full Text] [Related]
2. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021.
Martínez-Baz I; Trobajo-Sanmartín C; Miqueleiz A; Guevara M; Fernández-Huerta M; Burgui C; Casado I; Portillo ME; Navascués A; Ezpeleta C; Castilla J; ;
Euro Surveill; 2021 Sep; 26(39):. PubMed ID: 34596016
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain).
Chico-Sánchez P; Gras-Valentí P; Algado-Sellés N; Jiménez-Sepúlveda N; Vanaclocha H; Peiró S; Burgos JS; Berenguer A; Navarro D; Sánchez-Payá J;
Prev Med; 2022 Oct; 163():107237. PubMed ID: 36057393
[TBL] [Abstract][Full Text] [Related]
4. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.
Martínez-Baz I; Trobajo-Sanmartín C; Miqueleiz A; Casado I; Navascués A; Burgui C; Ezpeleta C; Castilla J; Guevara M; ;
Euro Surveill; 2023 Feb; 28(5):. PubMed ID: 36729113
[TBL] [Abstract][Full Text] [Related]
5. Effect of COVID-19 vaccination on the SARS-CoV-2 transmission among social and household close contacts: A cohort study.
Martínez-Baz I; Miqueleiz A; Egüés N; Casado I; Burgui C; Echeverría A; Navascués A; Fernández-Huerta M; García Cenoz M; Trobajo-Sanmartín C; Guevara M; Ezpeleta C; Castilla J
J Infect Public Health; 2023 Mar; 16(3):410-417. PubMed ID: 36724697
[TBL] [Abstract][Full Text] [Related]
6. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January-May 2021, Aragon, Spain.
Del Cura-Bilbao A; López-Mendoza H; Chaure-Pardos A; Vergara-Ugarriza A; Guimbao-Bescós J
Emerg Infect Dis; 2022 Mar; 28(3):591-598. PubMed ID: 35195514
[TBL] [Abstract][Full Text] [Related]
8. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study.
Shrotri M; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Giddings R; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
Lancet Healthy Longev; 2022 Jul; 3(7):e470-e480. PubMed ID: 35813279
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021.
Mazagatos C; Monge S; Olmedo C; Vega L; Gallego P; Martín-Merino E; Sierra MJ; Limia A; Larrauri A; ;
Euro Surveill; 2021 Jun; 26(24):. PubMed ID: 34142647
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness of vaccines against SARS-CoV-2 used in Spain: infection, hospitalization and mortality in people aged fifty/fifty-nine.].
Monge S; Mazagatos C; Olmedo C; Rojas-Benedicto A; Simón F; Vega-Piris L; Sierra MJ; Limia A; Larrauri A
Rev Esp Salud Publica; 2022 Sep; 96():. PubMed ID: 36052820
[TBL] [Abstract][Full Text] [Related]
11. Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland.
Anderegg N; Althaus CL; Colin S; Hauser A; Laube A; Mäusezahl M; Wagner M; Zaffora B; Riou J
Swiss Med Wkly; 2022 Apr; 152():w30163. PubMed ID: 35752951
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021.
Harder T; Külper-Schiek W; Reda S; Treskova-Schwarzbach M; Koch J; Vygen-Bonnet S; Wichmann O
Euro Surveill; 2021 Oct; 26(41):. PubMed ID: 34651577
[TBL] [Abstract][Full Text] [Related]
14. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort.
Arregocés-Castillo L; Fernández-Niño J; Rojas-Botero M; Palacios-Clavijo A; Galvis-Pedraza M; Rincón-Medrano L; Pinto-Álvarez M; Ruiz-Gómez F; Trejo-Valdivia B
Lancet Healthy Longev; 2022 Apr; 3(4):e242-e252. PubMed ID: 35340743
[TBL] [Abstract][Full Text] [Related]
18. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
Front Immunol; 2022; 13():940562. PubMed ID: 36091023
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
